AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln (updated)

Icosavax

12/12/2023 07:19

(Adds details on deal throughout)
       Dec 12 (Reuters) - Drugmaker AstraZeneca  AZN.L  on
Tuesday agreed to buy vaccine developer Icosavax  ICVX.O  in a
deal valued at up to $1.1 billion to bolster its respiratory
syncytial virus (RSV) vaccine portfolio.
    The deal values Icosavax at $15 per share in cash at
closing, plus a non-tradable contingent value right for up to $5
per share in cash if certain milestones are met.
    The upfront payment of $15 apiece represents a premium of
about 43% to U.S.-listed Icosavax's last close. 
        
  

 (Reporting by Yadarisa Shabong in Bengaluru; Editing by Sonia
Cheema)
 ((Yadarisa.Shabong@thomsonreuters.com; +91 9742735150;))